Amgen reports that it beats analysts’ expectations in its latest quarter and raises its 2026 guidance. According to a transcript of the company’s earnings call, Amgen outperforms on both earnings per share and revenue versus what the market expected for the quarter. The company also increases its outlook for full-year 2026, adjusting both EPS and revenue targets upward, signaling improved expectations for its business performance going forward. The Seeking Alpha report similarly states that Amgen lifts its 2026 EPS and revenue guidance after the quarter comes in ahead on both lines. Across the sources, the core points are that Q2 results exceed estimates and that management responds by revising higher guidance for 2026, rather than maintaining prior projections. The articles do not indicate any contrary results in the coverage provided, and both emphasize the same sequence: a better-than-expected quarter and an accompanying upward update to the company’s forward-looking financial expectations.